Biblio

[ Author(Desc)] Title Type Year
Filters: Author is Salas, Maria Queralt  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Salas MQueralt, Prem S, Atenafu EG, Law ADatt, Lam W, Al-Shaibani Z, Loach D, Kim DDong Hwan, Michelis FV, Lipton JHoward, et al. Reduced Intensity Allogeneic Stem Cell Transplant with Anti-Thymocyte globulin and Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia. Eur J Haematol. 2019.
Salas MQueralt, Lam W, Law ADatt, Kim DDong Hwan, Michelis FV, Loach D, Al-Shaibani Z, Lipton JHoward, Kumar R, Mattsson J, et al. Reduced Intensity Conditioning Allogeneic Transplant with Dual T-cell Depletion in Myelofibrosis. Eur J Haematol. 2019.
Salas MQueralt, Lam SChenc Wils, Pasic I, Gerbitz A, Michelis FV, Kim DDong Hwan, Al-Shaibani Z, Lipton JHoward, Mattsson J, Kumar R, et al. Less is More: Superior GVHD-Free/Relapse-Free Survival with Reduced Intensity Conditioning and Dual T-cell Depletion in AML. Biol Blood Marrow Transplant. 2020.
Salas MQueralt, Charry P, Pedraza A, Martínez-Cibrián N, Solano MTeresa, Domenech A, Suárez-Lledó M, Nomdedeu M, Cid J, Lozano M, et al. PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT. Transplant Cell Ther. 2022.
Salas MQueralt, Pedraza A, Charry P, Suárez-Lledó M, Rodríguez-Lobato LGerardo, Brusosa M, Solano MTeresa, Serrahima A, Nomdedeu M, Cid J, et al. Post-transplant Cyclophosphamide and Tacrolimus for GVHD Prevention Allo-HCT from HLA-Matched Donors Generates more Advantages than Limitations. Transplant Cell Ther. 2023.